Nov 21 2024 17 mins
Visit https://www.peervoice.com/WQK860 to view the entire programme with slides. After completing “Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations”, participants will be able to: Describe resistance mechanisms with targeted therapies for patients with advanced non-small cell lung cancer (NSCLC) harbouring rare actionable genomic alterations (AGAs); Discuss how to address resistance mechanisms in patients receiving targeted therapies; Assess the evidence of central nervous system (CNS) activity with key targeted therapies for advanced NSCLC with rare AGAs; and Outline the potential implications of the evidence on management decisions and patient outcomes.